Bosutinib: A third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia

Brittany G. Hill, Vamsi K. Kota, Hanna Jean Khoury

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Bosutinib is an oral tyrosine kinase inhibitor (TKI) with very potent dual inhibitory activity against SRC and abelson gene. Bosutinib was approved in 2012 for the treatment of resistant Philadelphia chromosome positive chronic myeloid leukemia (CML). Bosutinib is a very effective TKI against all phases of intolerant or resistant CML regardless of the presence or absence of an abelson gene domain mutation, except for cases with detectable T315I or V299L. Bosutinib is overall well tolerated and associated with a unique, but manageable toxicity profile. Factors that influence the prescribing pattern of this drug are complex and include physicians', and increasingly patients and families' preference, patients' comorbid conditions, schedule of administration, as well as financial factors. This paper provides an overview of CML, the TKI market, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of bosutinib.

Original languageEnglish (US)
Pages (from-to)765-770
Number of pages6
JournalExpert Review of Anticancer Therapy
Volume14
Issue number7
DOIs
StatePublished - Jul 2014

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics
Drug Prescriptions
Philadelphia Chromosome
Patient Preference
Genes
Appointments and Schedules
Pharmacokinetics
bosutinib
Physicians
Safety
Mutation

Keywords

  • Bosutinib
  • Chronic myeloid leukemia
  • Resistant
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Bosutinib : A third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. / Hill, Brittany G.; Kota, Vamsi K.; Khoury, Hanna Jean.

In: Expert Review of Anticancer Therapy, Vol. 14, No. 7, 07.2014, p. 765-770.

Research output: Contribution to journalReview article

@article{dd12343ff45e4b23812d6bc1d1b1d49c,
title = "Bosutinib: A third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia",
abstract = "Bosutinib is an oral tyrosine kinase inhibitor (TKI) with very potent dual inhibitory activity against SRC and abelson gene. Bosutinib was approved in 2012 for the treatment of resistant Philadelphia chromosome positive chronic myeloid leukemia (CML). Bosutinib is a very effective TKI against all phases of intolerant or resistant CML regardless of the presence or absence of an abelson gene domain mutation, except for cases with detectable T315I or V299L. Bosutinib is overall well tolerated and associated with a unique, but manageable toxicity profile. Factors that influence the prescribing pattern of this drug are complex and include physicians', and increasingly patients and families' preference, patients' comorbid conditions, schedule of administration, as well as financial factors. This paper provides an overview of CML, the TKI market, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of bosutinib.",
keywords = "Bosutinib, Chronic myeloid leukemia, Resistant, Tyrosine kinase inhibitor",
author = "Hill, {Brittany G.} and Kota, {Vamsi K.} and Khoury, {Hanna Jean}",
year = "2014",
month = "7",
doi = "10.1586/14737140.2014.924400",
language = "English (US)",
volume = "14",
pages = "765--770",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Bosutinib

T2 - A third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia

AU - Hill, Brittany G.

AU - Kota, Vamsi K.

AU - Khoury, Hanna Jean

PY - 2014/7

Y1 - 2014/7

N2 - Bosutinib is an oral tyrosine kinase inhibitor (TKI) with very potent dual inhibitory activity against SRC and abelson gene. Bosutinib was approved in 2012 for the treatment of resistant Philadelphia chromosome positive chronic myeloid leukemia (CML). Bosutinib is a very effective TKI against all phases of intolerant or resistant CML regardless of the presence or absence of an abelson gene domain mutation, except for cases with detectable T315I or V299L. Bosutinib is overall well tolerated and associated with a unique, but manageable toxicity profile. Factors that influence the prescribing pattern of this drug are complex and include physicians', and increasingly patients and families' preference, patients' comorbid conditions, schedule of administration, as well as financial factors. This paper provides an overview of CML, the TKI market, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of bosutinib.

AB - Bosutinib is an oral tyrosine kinase inhibitor (TKI) with very potent dual inhibitory activity against SRC and abelson gene. Bosutinib was approved in 2012 for the treatment of resistant Philadelphia chromosome positive chronic myeloid leukemia (CML). Bosutinib is a very effective TKI against all phases of intolerant or resistant CML regardless of the presence or absence of an abelson gene domain mutation, except for cases with detectable T315I or V299L. Bosutinib is overall well tolerated and associated with a unique, but manageable toxicity profile. Factors that influence the prescribing pattern of this drug are complex and include physicians', and increasingly patients and families' preference, patients' comorbid conditions, schedule of administration, as well as financial factors. This paper provides an overview of CML, the TKI market, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of bosutinib.

KW - Bosutinib

KW - Chronic myeloid leukemia

KW - Resistant

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84903161718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903161718&partnerID=8YFLogxK

U2 - 10.1586/14737140.2014.924400

DO - 10.1586/14737140.2014.924400

M3 - Review article

C2 - 24875651

AN - SCOPUS:84903161718

VL - 14

SP - 765

EP - 770

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 7

ER -